Skip to content

US · HCWB · BIOTECHNOLOGY

HCW Biologics Inc. (HCWB) intrinsic value and stock valuation

$0.75as of 2026-11-21 · Mkt cap 1.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

HCW Biologics Inc. DCF and intrinsic value

InvestorsCraft values HCWB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HCWB’s statements →

HCW Biologics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miramar, FL 33025 hcwbiologics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$50K-58.6% 5y CAGRd
20192025
Net income
-$-7.96M
20192025
Free cash flow
-$-13.39M
20192025
Total equity
$2.76M-28.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$50K$2.57M$2.84M$6.72M$0.00
Operating income-$-11.26M-$-29.48M-$-25.72M-$-15.08M-$-13.37M
Net income-$-7.96M-$-30.02M-$-24.99M-$-14.9M-$-12.86M
EPSd-$-22.74M-$-4.64M-$-4.17M-$-2.5M-$-2.16M
Operating cash flow-$-13.39M-$-14.23M-$-22.51M-$-10.39M-$-10.98M
Capital expenditure-$0.00-$-260K-$-6.2M-$-10.28M-$-50K
Free cash flow-$-13.39M-$-14.49M-$-28.72M-$-20.66M-$-11.02M
Total assets$24.5M$30.2M$28.5M$46.8M$53.5M
Total debt$6.81M$13.7M$6.3M$6.41M$0.00
Net debt$4.86M$9.02M$2.71M-$-15.92M-$-11.73M
Total equity$2.76M-$-6.77M$13.5M$37.4M$51.2M
Cash and short-term investments$1.95M$4.67M$3.6M$32.1M$36.7M
Income statement
20252024202320222021
Revenue$50K$2.57M$2.84M$6.72M$0.00
Cost of revenue$40K$1.61M$2.28M$4.14M$0.00
Gross profit$10K$960K$560K$2.59M$0.00
Research and development expenses$5.44M$6.39M$7.68M$9.34M$8.17M
Selling, general and administrative expenses$7.7M$22M$13.1M$7.99M$5.3M
Other expenses-$-1.88M$2.1M$5.52M$340K-$-110K
Operating expenses$11.3M$30.4M$26.3M$17.7M$13.4M
Cost and expenses$11.3M$32.1M$28.6M$21.8M$13.4M
Interest income$0.00$0.00$0.00$0.00$510K
Interest expense$1.25M$1.16M$280K$130K$0.00
Depreciation and amortization$1.04M$1.18M$1.14M$720K$540K
Ebitda-$-5.67M-$-27.68M-$-23.58M-$-14.06M-$-12.32M
Operating income-$-11.26M-$-29.48M-$-25.72M-$-15.08M-$-13.37M
Total other income/expenses, net$3.3M-$-540K$720K$180K$510K
Income before tax-$-7.96M-$-30.02M-$-24.99M-$-14.9M-$-12.86M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.96M-$-30.02M-$-24.99M-$-14.9M-$-12.86M
Weighted average shares outstanding$350K$6.47M$5.99M$5.97M$5.96M
Weighted average diluted shares outstanding$350K$6.47M$5.99M$5.97M$5.96M
Balance sheet
20252024202320222021
Cash and short-term investments$1.95M$4.67M$3.6M$32.1M$36.7M
Net receivables$30K$580K$1.54M$420K$130K
Inventory$0.00$0.00$0.00$1.39M$0.00
Total current assets$2.28M$5.7M$6.4M$34.1M$40.5M
Property, plant and equipment, net$20.9M$22.9M$20.5M$10.8M$1.12M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.33M$1.6M$1.6M$1.6M$11.5M
Total non-current assets$22.2M$24.5M$22.1M$12.7M$13M
Total assets$24.5M$30.2M$28.5M$46.8M$53.5M
Accounts payable$13.1M$22.3M$6.17M$1.23M$220K
Short-term debt$6.81M$6.31M$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$1.8M
Total current liabilities$21.1M$29.6M$8.75M$2.96M$2.32M
Long-term debt$0.00$7.38M$6.3M$6.41M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$690K$7.38M$6.3M$6.42M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$21.8M$37M$15.1M$9.38M$2.32M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-108.52M-$-100.56M-$-70.53M-$-45.54M-$-30.64M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.76M-$-6.77M$13.5M$37.4M$51.2M
Total investments$1.33M$1.6M$1.6M$11.3M$36.5M
Total debt$6.81M$13.7M$6.3M$6.41M$0.00
Net debt$4.86M$9.02M$2.71M-$-15.92M-$-11.73M
Cash flow statement
20252024202320222021
Net income-$-7.96M-$-30.02M-$-24.99M-$-14.9M-$-12.86M
Depreciation and amortization$1.04M$1.18M$1.14M$720K$540K
Stock-based compensation$770K$1.01M$1M$1.12M$360K
Change in working capital-$-2.78M$13.6M-$-4.64M$2.49M$1.46M
Accounts receivable$550K$950K-$-1.12M-$-280K$2.37M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.47M$11.9M$1.62M$420K$1.89M
Net cash provided by operating activities-$-13.39M-$-14.23M-$-22.51M-$-10.39M-$-10.98M
Investments in property, plant and equipment$0.00-$-260K-$-6.2M-$-10.28M-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-260K$3.8M$14.7M-$-35.02M
Common stock issued$11.9M$6.46M$20K$20K$56M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.7M$15.6M-$-10K$6.27M$49.3M
Net change in cash-$-2.72M$1.08M-$-18.73M$10.6M$3.27M
Cash at end of period$1.95M$4.67M$3.6M$22.3M$11.7M
Operating cash flow-$-13.39M-$-14.23M-$-22.51M-$-10.39M-$-10.98M
Capital expenditure-$0.00-$-260K-$-6.2M-$-10.28M-$-50K
Free cash flow-$-13.39M-$-14.49M-$-28.72M-$-20.66M-$-11.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About HCW Biologics Inc.

        HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

        CEO
        Hing C. Wong
        Employees
        35
        Beta
        2.30

        Explore

        Frequently asked questions

        What is the intrinsic value of HCW Biologics Inc. (HCWB)?

        InvestorsCraft does not currently publish an intrinsic value for HCWB. How the IC value is calculated.

        Is HCWB undervalued?

        InvestorsCraft does not publish an undervaluation signal for HCWB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.